Cargando…

The role of biosimilars in value-based oncology care

Biopharmaceuticals (biologics) represent one of the fastest growing sectors of cancer treatment. They are recommended for treating underlying cancer and as supportive care for management of treatment side effects. Given the high costs of cancer care and the need to balance health care provision and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Kashyap B, Arantes, Luiz H, Tang, Wing Yu, Fung, Selwyn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199968/ https://www.ncbi.nlm.nih.gov/pubmed/30410395 http://dx.doi.org/10.2147/CMAR.S164201

Ejemplares similares

Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
por: Scheinberg, Morton, et al.
Publicado: (2018)

Current and future roles of biosimilars in oncology practice
por: Konstantinidou, Sofia, et al.
Publicado: (2020)

Biosimilars in oncology
por: Tabernero, Josep
Publicado: (2018)

Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective
por: Aapro, Matti, et al.
Publicado: (2019)

Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars
por: Stebbing, Justin, et al.
Publicado: (2020)

Preparing for the incoming wave of biosimilars in oncology
por: Wolff-Holz, Elena, et al.
Publicado: (2018)

Clinical considerations for the development of biosimilars in oncology
por: Socinski, Mark A, et al.
Publicado: (2015)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Oncology biosimilars: New developments and future directions
por: Bachu, Rinda Devi, et al.
Publicado: (2022)

Emerging Role of Biosimilars in Oncology-Hematology in Saudi Arabia: A Practical Perspective
por: Khan, Mansoor A., et al.
Publicado: (2019)

Development of biosimilars in an era of oncologic drug shortages
por: Li, Edward, et al.
Publicado: (2015)

Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015)

Biosimilars in Oncology: Latest Trends and Regulatory Status
por: Joshi, Deeksha, et al.
Publicado: (2022)

Tendering and biosimilars: what role for value-added services?
por: Simoens, Steven, et al.
Publicado: (2019)

Presently available biosimilars in hematology-oncology: G-CSF
por: Gascon, Pere
Publicado: (2012)

Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
por: Francescon, Sara, et al.
Publicado: (2016)

Biosimilar agents in oncology/haematology: from approval to practice
por: Niederwieser, Dietger, et al.
Publicado: (2011)

Biosimilars in the United States: Considerations for Oncology Advanced Practitioners
por: Mayden, Kelley D., et al.
Publicado: (2015)

Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner
por: Campen, Christopher J.
Publicado: (2017)

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
por: Tabernero, Josep, et al.
Publicado: (2017)

Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis
por: Simoens, Steven, et al.
Publicado: (2017)

Risk management of biosimilars in oncology: each medicine is a work in progress
por: Vulto, Arnold G., et al.
Publicado: (2012)

Correction: Preparing for the incoming wave of biosimilars in oncology
Publicado: (2018)

Barriers to Oncology Biosimilars Uptake in the United States
por: Nabhan, Chadi, et al.
Publicado: (2018)

Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice
por: Mayden, Kelley D., et al.
Publicado: (2022)

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology
por: Giuliani, Rosa, et al.
Publicado: (2019)

Potential of Biosimilars to Increase Access to Biologics: Considerations for Advanced Practice Providers in Oncology
por: Tinsley, Sara M., et al.
Publicado: (2018)

Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
por: Monk, Bradley J., et al.
Publicado: (2017)

Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes
por: Uno, Hajime, et al.
Publicado: (2019)

Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients
por: Najeeb, Hala, et al.
Publicado: (2022)

The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC)
por: Fernandes, G.S., et al.
Publicado: (2018)

Extrapolation concept at work with biosimilar: a decade of experience in oncology
por: Krendyukov, Andriy, et al.
Publicado: (2018)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
por: Uifălean, Alina, et al.
Publicado: (2018)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Improving Access to Cancer Treatments: The Role of Biosimilars
por: Chopra, Rakesh, et al.
Publicado: (2017)

Editorial: Biological drugs and biosimilars in autoimmune diseases
por: Wajda, Anna, et al.
Publicado: (2023)

Pegfilgrastim Biosimilars in US Supportive Oncology: A Narrative Review of Administration Options and Economic Considerations to Maximize Patient Benefit
por: Humphreys, Sophia Z., et al.
Publicado: (2022)

Biosimilars in dermatology
por: Mazur, Małgorzata, et al.
Publicado: (2015)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing
por: Cook, John W., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qbl179uj86k2rv67obfjbttk6g